open access

Vol 47, No 4 (2013)
ARTYKUŁ ORYGINALNY
Submitted: 2012-02-03
Get Citation

Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas

Krzysztof Majchrzak, Wojciech Kaspera, Janusz Szymaś, Barbara Bobek-Billewicz, Anna Hebda, Henryk Majchrzak
DOI: 10.5114/ninp.2013.36757
·
Neurol Neurochir Pol 2013;47(4):325-331.

open access

Vol 47, No 4 (2013)
ARTYKUŁ ORYGINALNY
Submitted: 2012-02-03

Abstract

Background and purpose

Antigens CD31 and CD34 and relative cerebral blood volume (rCBV) in gliomas reflect in different ways neoangiogenesis of the tumour. Thus, we decided: (1) to estimate the correlation between the values of CD31 and CD34 and the value of rCBV in low-grade gliomas (LGG), and (2) to establish the prognostic value of these markers.

Material and methods

The investigated group consisted of 53 patients with LGG who were operated on in the Neurosurgical Department at Sosnowiec between 2005 and 2011. On the basis of perfusion-weighted imaging (PWI-MRI) in the tumour texture, rCBV was calculated. The values of CD31 and CD34 were estimated on the basis of immunohistochemical investigation. Three outcome measures were assessed: (1) overall survival, (2) progression-free survival, and (3) malignant-free survival. Statistical analyses were done using the STATISTICA 9.0 program.

Results

Higher value of rCBV in the texture of TGG significantly correlated with higher CD31 (p = 0.0006) and CD34 values (p = 0.0043). Progression-free survival was significantly longer in patients with rCBV < 1.75 than for persons with rCBV > 1.75 (p = 0.015). Lower expression of CD31 correlated with probability of longer survival of the patients after the operation of LGG (p = 0.068).

Conclusions

Density of microvessels as assessed immunohistochemically with CD31+ and CD34+ in LGG correlated with the value of rCBV in the tumour. The value of 1.75 for rCBV may be the threshold for better or poorer outcome of these patients. Expression of CD31 antigen is an important prognostic factor for the time of survival for patients with TGG.

Abstract

Background and purpose

Antigens CD31 and CD34 and relative cerebral blood volume (rCBV) in gliomas reflect in different ways neoangiogenesis of the tumour. Thus, we decided: (1) to estimate the correlation between the values of CD31 and CD34 and the value of rCBV in low-grade gliomas (LGG), and (2) to establish the prognostic value of these markers.

Material and methods

The investigated group consisted of 53 patients with LGG who were operated on in the Neurosurgical Department at Sosnowiec between 2005 and 2011. On the basis of perfusion-weighted imaging (PWI-MRI) in the tumour texture, rCBV was calculated. The values of CD31 and CD34 were estimated on the basis of immunohistochemical investigation. Three outcome measures were assessed: (1) overall survival, (2) progression-free survival, and (3) malignant-free survival. Statistical analyses were done using the STATISTICA 9.0 program.

Results

Higher value of rCBV in the texture of TGG significantly correlated with higher CD31 (p = 0.0006) and CD34 values (p = 0.0043). Progression-free survival was significantly longer in patients with rCBV < 1.75 than for persons with rCBV > 1.75 (p = 0.015). Lower expression of CD31 correlated with probability of longer survival of the patients after the operation of LGG (p = 0.068).

Conclusions

Density of microvessels as assessed immunohistochemically with CD31+ and CD34+ in LGG correlated with the value of rCBV in the tumour. The value of 1.75 for rCBV may be the threshold for better or poorer outcome of these patients. Expression of CD31 antigen is an important prognostic factor for the time of survival for patients with TGG.

Get Citation

Keywords

low-grade gliomas, outcome, CD31, CD34, rCBV

About this article
Title

Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 47, No 4 (2013)

Pages

325-331

DOI

10.5114/ninp.2013.36757

Bibliographic record

Neurol Neurochir Pol 2013;47(4):325-331.

Keywords

low-grade gliomas
outcome
CD31
CD34
rCBV

Authors

Krzysztof Majchrzak
Wojciech Kaspera
Janusz Szymaś
Barbara Bobek-Billewicz
Anna Hebda
Henryk Majchrzak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl